Molecular and immunohistochemical characterization of ERBB2 activating mutations in low‐grade serous ovarian carcinoma
Histopathology · 2025
DOI: 10.1111/his.15452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2025. Verfasst von Alexander J Neil und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Brigham and Women's Hospital.
Abstract (Originalsprache)
Aims
Low‐grade serous carcinoma (LGSC) of the ovary presents unique therapeutic challenges due to its resistance to platinum‐based chemotherapies and a tendency to present at an advanced stage. Approximately 50% of LGSC possess activating mutations in KRAS , NRAS, and BRAF , a finding associated with better overall survival. However, many tumours lack obvious driver alterations against which to direct targeted treatment strategies, necessitating further investigation into molecular drivers of LGSC and their impact on clinical outcomes. Methods and Results We conducted a retrospective analysis of 84 LGSC patients who underwent tumour‐only targeted next‐generation sequencing at our institution. Molecular data were correlated with clinical outcomes, HER2 immunohistochemistry, and supplemented with additional tumour sequencing data from the AACR GENIE cohort v15.1 ( n = 295). Approximately 5% of LGSC cases across the combined cohort harboured activating alterations in ERBB2 ( n = 17/369), which encodes the HER2 receptor tyrosine kinase. These alterations were mutually exclusive of other MAP kinase pathway mutations and included exon 20 insertions ( n = 6), extracellular domain/transmembrane domain missense alterations ( n = 4), and exon 16 skipping mutations ( n = 7). ERBB2 exon 16 emerged as a mutational hotspot in LGSC when compared to other tumour types. Immunohistochemistry revealed variable HER2 expression patterns that were independent of ERBB2 mutational status. In our institutional cohort, patients with RAS/RAF mutant tumours ( n = 38) showed better overall survival compared to RAS/RAF wildtype tumours ( n = 35). No tumours in our internal cohort ( n = 84) harboured ERBB2 amplifications.
Conclusion
As the landscape of HER2‐directed therapies continues to evolve, these findings suggest that ERBB2 alterations and HER2 expression may represent a potential therapeutic target in LGSC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Pathology, University of Rochester Medical Center, University of Rochester School of Medicine, Rochester, NY, USA.
- Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Alexander J Neil, Dingani Nkosi, Ju-Yoon Yoon, David L Kolin, Lynette M Sholl
Förderung
- Brigham and Women's Hospital
Zitieren
APA
Neil, A. J., Nkosi, D., Yoon, J. Y., Kolin, D. L., & Sholl, L. M. (2025). Molecular and immunohistochemical characterization of ERBB2 activating mutations in low‐grade serous ovarian carcinoma. Histopathology. https://doi.org/10.1111/his.15452
Vancouver
Neil AJ, Nkosi D, Yoon JY, Kolin DL, Sholl LM. Molecular and immunohistochemical characterization of ERBB2 activating mutations in low‐grade serous ovarian carcinoma. Histopathology. 2025. doi:10.1111/his.15452
BibTeX
@article{Neil2025,
author = {Neil, Alexander J and Nkosi, Dingani and Yoon, Ju-Yoon and Kolin, David L and Sholl, Lynette M},
title = {Molecular and immunohistochemical characterization of ERBB2 activating mutations in low‐grade serous ovarian carcinoma},
journal = {Histopathology},
year = {2025},
doi = {10.1111/his.15452}
}
EUVIMED